{"analyses":[{"ciLowerLimit":"0.544","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.331","estimateComment":"The hazard ratio was obtained from a stratified Cox model using cGvHD severity at randomization as strata.","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.2396","pValueComment":"The p-value was derived from a 1-sided stratified log-rank test.","paramType":"Hazard Ratio (HR)","paramValue":"0.851","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"The median and upper and lower limits of the confidence interval were not estimable because too few participants died.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The median and upper limit of the confidence interval were not estimable because too few participants died.","groupId":"OG001","lowerLimit":"41.0","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"164"}],"units":"Participants"}],"description":"Overall survival was defined as the time from the date of randomization to the date of death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ruxolitinib was administered orally twice per day at a dose of 10 milligrams (mg).","id":"OG000","title":"Ruxolitinib"},{"description":"Participants received best available therapies (BATs), including, but not limited to, extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), infliximab, rituximab, pentostatin, imatinib, and ibrutinib based on the investigator's decision.","id":"OG001","title":"Best Available Therapy"}],"paramType":"MEDIAN","populationDescription":"FAS","reportingStatus":"POSTED","timeFrame":"from the date of randomization to the date of death due to any cause up to LPLV (approximately 5 years)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}